Quantcast
Last updated on April 21, 2014 at 7:52 EDT

Latest Axitinib Stories

2014-01-24 08:24:33

HAIFA, Israel, Jan. 24, 2014 /PRNewswire/ -- Novocure announced today that the first patient has enrolled in the EF-20 Study, an open label, pilot clinical trial of NovoTTF Therapy plus gemcitabine as first-line therapy for patients with locally advanced and metastatic pancreatic adenocarcinoma. NovoTTF Therapy is an anti-mitotic treatment delivered continuously with a wearable, home-use medical device. "The EF-20 study builds on extensive preclinical research demonstrating the...

2013-09-20 23:04:05

The celebrity-hosted program will feature SFL Pharmaceuticals in an upcoming Medical Minutes segment. Coral Springs, FL (PRWEB) September 20, 2013 The producers of Health Briefs TV are pleased to announce that SFJ Pharmaceuticals will be featured in an upcoming segment on "Innovative Drug Development and Clinical Research Driving Improved Patient Care" as part of the show's Medical Minutes series. Their value of pharmaceuticals is especially evident in the field of...

2012-09-07 02:24:04

SAN FRANCISCO, September 7, 2012 /PRNewswire/ -- Phase 3 Trial to be Conducted Across Sites in Asia and Europe The SFJ Pharmaceuticals Group (SFJ), announced today that it has entered into a collaborative development agreement with Pfizer Inc. to conduct a Phase 3 clinical trial of Pfizer's investigational pan-HER (pan-human epidermal growth factor receptor) inhibitor, dacomitinib (PF-00299804). The trial, which will be conducted across multiple sites in Asia...

2012-04-03 09:00:10

The combination of the novel drug TH-302 with the standard drug gemcitabine has shown early signs of delaying the worsening of cancer in patients with advanced pancreatic cancer, a Mayo Clinic-led study has found. This was evaluated using a measure termed progression-free survival (PFS). According to the results of a multi-center Phase II clinical trial, patients receiving the combination of gemcitabine and TH-302 demonstrated a progression-free survival of 5.6 months compared to 3.6 months...

2012-04-03 08:44:26

Additional compounds may help first-line drug kill cancer cells, according to new research by scientists at Fox Chase Cancer Center Scientists at Fox Chase Cancer Center are developing a new way to treat pancreatic cancer by boosting the effects of gemcitabine (Gemzar)–the chemotherapy drug that is considered standard therapy for the disease. Although gemcitabine is the first line of defense against pancreatic cancer, many cells find ways to evade the treatment. The new research,...

2012-04-03 02:27:41

CHICAGO, April 3, 2012 /PRNewswire/ -- CureFAKtor Pharmaceuticals, LLC, a privately-held biopharmaceutical company focused on the research and development of Focal Adhesion Kinase (FAK) inhibitors for cancer, today presented preclinical research results at the 2012 AACR Annual Meeting in Chicago, Illinois demonstrating that analogs of novel FAK inhibitor CFAK-C4 disrupted FAK-vascular endothelial growth factor receptor 3 (FAK-VEGFR3) interaction and inhibited pancreatic tumor growth. The...

2012-01-30 18:10:00

BioPlus Specialty Pharmacy selected as one of the limited number of specialty pharmacies with access to this advanced renal cell carcinoma second line therapy. Altamonte Springs, Florida (PRWEB) January 30, 2012 BioPlus Specialty Pharmacy (BioPlus), one of the nation´s leading specialty pharmacies, has launched axitinib (brand name: Inlyta, from Pfizer), a new cancer drug just approved by the FDA. BioPlus is pleased to be one of the small number of specialty pharmacies with access to...

2012-01-09 03:05:00

SAN FRANCISCO, January 9, 2012 /PRNewswire/ -- SFJ Pharma Ltd. II (President & CEO: Robert F. DeBenedetto, "SFJ") announced today that it has entered into a collaborative development agreement with Pfizer Inc. to conduct a Phase 3 clinical trial in Asia of Pfizer's investigational agent axitinib for the adjuvant treatment of patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy. Axitinib is an oral and selective inhibitor of vascular...

2011-10-05 07:00:00

SAN DIEGO, Oct. 5, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced the commencement of patient dosing in a Phase 2 clinical trial with pegylated rHuPH20 (PEGPH20) in patients with stage IV previously untreated pancreatic cancer. This multi-center, international, randomized,...

2010-11-19 06:55:00

NEW YORK, Nov. 19, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced today that the Phase 3 AXIS 1032 trial (A4061032), studying the investigational compound axitinib in previously treated patients with metastatic renal cell carcinoma (mRCC), has met its primary endpoint, demonstrating that axitinib significantly extended progression-free survival (PFS) when compared to sorafenib, in the study population. Consistent with previous analyses, axitinib demonstrated a generally...